STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, combined STAT3 and BCR-ABL1 inhibition can attenuate BCR-ABL1 kinase-dependent TKI resistance in chronic myeloid leukemia; additionally, combined with MEK inhibitors AZD6244, PD98059 and trametinib in KRASMT pancreatic and colon cancer cells, it increases the suppression of tumor growth [39,40].